Table 3.
Effect-size estimates of four blood routine derivates for colorectal cancer mortality by clinicopathologic features
| Subgroups | HR, 95% CI, P* | ||||
|---|---|---|---|---|---|
| NLR (per 2.05+) | PLR (per 140+) | LMR (per 3.62+) | MRR (per 0.13+) | ||
| TNM stage | I-II | 1.10, 0.99-1.21, 0.064 | 1.23, 1.01-1.51, 0.045 | 0.58, 0.35-0.98, 0.042 | 1.63, 1.04-2.56, 0.034 |
| III-IV | 1.21, 1.12-1.30, <0.001 | 1.25, 1.03-1.52, 0.024 | 0.64, 0.46-0.88, 0.005 | 1.38, 1.07-1.78, 0.014 | |
| Invasion depth | TI-T2 | 1.06, 0.82-1.36, 0.676 | 1.04, 0.68-1.60, 0.848 | 0.35, 0.13-0.96, 0.042 | 2.85, 1.45-5.61, 0.002 |
| T3-T4 | 1.12, 1.05-1.19, <0.001 | 1.15, 0.99-1.34, 0.065 | 0.67, 0.51-0.87, 0.003 | 1.31, 1.03-1.67, 0.029 | |
| Regional LNM | N0 | 1.13, 1.02-1.24, 0.015 | 1.23, 1.01-1.49, 0.037 | 0.52, 0.32-0.84, 0.008 | 1.89, 1.29-2.77, 0.001 |
| N1-N2 | 1.14, 1.06-1.23, <0.001 | 1.23, 1.00-1.51, 0.047 | 0.66, 0.48-0.92, 0.013 | 1.31, 1.00-1.72, 0.053 | |
| Distant metastasis | Negative | 1.11, 1.04-1.19, 0.003 | 1.12, 0.96-1.31, 0.145 | 0.67, 0.50-0.90, 0.007 | 1.39, 1.07-1.81, 0.015 |
| Positive | 1.14, 0.98-1.33, 0.090 | 1.21, 0.90-1.63, 0.209 | 0.72, 0.37-1.39, 0.331 | 1.31, 0.73-2.33, 0.361 | |
| Differentiation | High/moderate | 1.11, 1.01-1.21, 0.025 | 1.16, 1.00-1.36, 0.057 | 0.57, 0.41-0.80, 0.001 | 1.53, 1.16-2.02, 0.003 |
| Low | 1.10, 1.02-1.20, 0.017 | 1.16, 0.87-1.55, 0.303 | 0.76, 0.54-1.07, 0.113 | 1.29, 0.85-1.95, 0.230 | |
| Embolus | Negative | 1.32, 1.17-1.49, <0.001 | 1.38, 1.12-1.70, 0.002 | 0.45, 0.28-0.71, 0.001 | 1.54, 1.09-2.18, 0.015 |
| Positive | 1.10, 0.98-1.23, 0.114 | 1.39, 1.00-1.94, 0.052 | 0.75, 0.50-1.13, 0.168 | 2.04, 1.28-3.23, 0.003 | |
| Tumor size | ≤ 4.5 cm | 1.10, 0.99-1.22, 0.082 | 1.01, 0.80-1.27, 0.947 | 0.61, 0.40-0.91, 0.015 | 1.84, 1.25-2.70, 0.002 |
| > 4.5 cm | 1.11, 1.03-1.20, 0.004 | 1.26, 1.05-1.51, 0.014 | 0.67, 0.48-0.95, 0.023 | 1.25, 0.92-1.68, 0.150 | |
Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval; NLR, Neutrophil-to-lymphocyte ratio; PLR, Platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; MRR, monocyte-to-red blood cell count ratio; TNM, tumor-node-metastasis; LNM, lymph node metastasis. *P was adjusted for age, sex, body mass index, smoking, drinking and family cancer history.